Historical Valuation
Transmedics Group Inc (TMDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.11 is considered Undervalued compared with the five-year average of -8.02. The fair price of Transmedics Group Inc (TMDX) is between 591.64 to 809.35 according to relative valuation methord. Compared to the current price of 136.09 USD , Transmedics Group Inc is Undervalued By 77%.
Relative Value
Fair Zone
591.64-809.35
Current Price：136.09
77%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Transmedics Group Inc (TMDX) has a current Price-to-Book (P/B) ratio of 11.79. Compared to its 3-year average P/B ratio of 16.15 , the current P/B ratio is approximately -26.98% higher. Relative to its 5-year average P/B ratio of 14.05, the current P/B ratio is about -16.06% higher. Transmedics Group Inc (TMDX) has a Forward Free Cash Flow (FCF) yield of approximately 2.88%. Compared to its 3-year average FCF yield of -3.07%, the current FCF yield is approximately -193.76% lower. Relative to its 5-year average FCF yield of -3.65% , the current FCF yield is about -178.83% lower.
P/B
Median3y
16.15
Median5y
14.05
FCF Yield
Median3y
-3.07
Median5y
-3.65
Competitors Valuation Multiple
AI Analysis for TMDX
The average P/S ratio for TMDX competitors is 99.95, providing a benchmark for relative valuation. Transmedics Group Inc Corp (TMDX.O) exhibits a P/S ratio of 6.11, which is -93.88% above the industry average. Given its robust revenue growth of 32.24%, this premium appears sustainable.
Performance Decomposition
AI Analysis for TMDX
1Y
3Y
5Y
Market capitalization of TMDX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TMDX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TMDX currently overvalued or undervalued?
Transmedics Group Inc (TMDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.11 is considered Undervalued compared with the five-year average of -8.02. The fair price of Transmedics Group Inc (TMDX) is between 591.64 to 809.35 according to relative valuation methord. Compared to the current price of 136.09 USD , Transmedics Group Inc is Undervalued By 77.00% .
What is Transmedics Group Inc (TMDX) fair value?
TMDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Transmedics Group Inc (TMDX) is between 591.64 to 809.35 according to relative valuation methord.
How does TMDX's valuation metrics compare to the industry average?
The average P/S ratio for TMDX's competitors is 99.95, providing a benchmark for relative valuation. Transmedics Group Inc Corp (TMDX) exhibits a P/S ratio of 6.11, which is -93.88% above the industry average. Given its robust revenue growth of 32.24%, this premium appears sustainable.
What is the current P/B ratio for Transmedics Group Inc (TMDX) as of Jan 10 2026?
As of Jan 10 2026, Transmedics Group Inc (TMDX) has a P/B ratio of 11.79. This indicates that the market values TMDX at 11.79 times its book value.
What is the current FCF Yield for Transmedics Group Inc (TMDX) as of Jan 10 2026?
As of Jan 10 2026, Transmedics Group Inc (TMDX) has a FCF Yield of 2.88%. This means that for every dollar of Transmedics Group Inc’s market capitalization, the company generates 2.88 cents in free cash flow.
What is the current Forward P/E ratio for Transmedics Group Inc (TMDX) as of Jan 10 2026?
As of Jan 10 2026, Transmedics Group Inc (TMDX) has a Forward P/E ratio of 47.80. This means the market is willing to pay $47.80 for every dollar of Transmedics Group Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Transmedics Group Inc (TMDX) as of Jan 10 2026?
As of Jan 10 2026, Transmedics Group Inc (TMDX) has a Forward P/S ratio of 6.11. This means the market is valuing TMDX at $6.11 for every dollar of expected revenue over the next 12 months.